| Title: |
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance |
| Authors: |
Calvisi, Diego; Boulter, Luke; Vaquero, Javier; Saborowski, Anna; Fabris, Luca; Rodrigues, Pedro; Coulouarn, Cédric; Castro, Rui; Segatto, Oreste; Raggi, Chiara; van der Laan, Luc; Carpino, Guido; Goeppert, Benjamin; Roessler, Stephanie; Kendall, Timothy; Evert, Matthias; Gonzalez-Sanchez, Ester; Valle, Juan; Vogel, Arndt; Bridgewater, John; Borad, Mitesh; Gores, Gregory; Roberts, Lewis; Marin, Jose; Andersen, Jesper; Alvaro, Domenico; Forner, Alejandro; Banales, Jesus; Cardinale, Vincenzo; Macias, Rocio; Vicent, Silve; Chen, Xin; Braconi, Chiara; Verstegen, Monique; Fouassier, Laura; Scheiter, Alexander; Selaru, Florin; Evert, Katja; Utpatel, Kirsten; Broutier, Laura; Cadamuro, Massimiliano; Huch, Meritxell; Goldin, Robert; Gradilone, Sergio; Saito, Yoshimasa |
| Contributors: |
University of Regensburg; University of Edinburgh (Edin.); Instituto de Salud Carlos III Madrid (ISC); Medizinische Hochschule Hannover = Hannover Medical School (MHH); Yale School of Medicine New Haven, Connecticut (YSM); Universidad del País Vasco Espainia / Euskal Herriko Unibertsitatea España = University of the Basque Country Spain = Université du pays basque Espagne (UPV / EHU); Oncogenesis, Stress, Signaling (OSS); Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC); UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM); CRLCC Eugène Marquis (CRLCC); UNICANCER; Universidade de Lisboa = University of Lisbon = Université de Lisbonne (ULISBOA); Università degli Studi di Firenze = University of Florence = Université de Florence (UniFI); Erasmus University Medical Center Rotterdam (Erasmus MC); Università degli studi di Roma “Foro Italico” Italia = Foro Italico University of Rome Italy Istituto Universitario di Scienze Motorie (UIMS) = University Institute of Motor Sciences; Heidelberg University Hospital Heidelberg; University of Barcelona; Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd); Liver Unit, Clínica Universitaria, CIBER-EHD; Institut d'Investigació Biomèdica de Bellvitge = Bellvitge Biomedical Research Institute (IDIBELL); The Christie NHS Foundation Trust Manchester, Royaume-Uni; University of Manchester Manchester; University College of London London (UCL); Mayo Clinic; Mayo Clinic Rochester; Universidad de Salamanca España = University of Salamanca Spain; University of Copenhagen = Københavns Universitet (UCPH); Università degli Studi di Roma "La Sapienza" = Sapienza University Rome (UNIROMA); Universidad Pública de Navarra Espagne = Public University of Navarra (UPNA); University of California San Francisco (UC San Francisco); University of California (UC); University of Glasgow; Centre de Recherche Saint-Antoine (CRSA); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU); The authors thank the European Network for the Study of Cholangiocarcinoma (ENS-CCA) and the European H2020 COST Action CA18122. The authors also acknowledge the valuable contributions of the external advisory panel. C.C. is supported by Inserm, Université de Rennes 1 and by a grant from the French Ministry of Health and the French National Cancer Institute (PRT-K20-136), CHU Rennes, CLCC Eugène Marquis, Rennes. M.M.A.V. and L.J.W.v.d.L. are supported by Medical Delta Regenerative Medicine 4D (Generating complex tissues with stem cells and printing technology) and TKI-LSH grant EMC-LSH19002. S.R. is supported by the German Research Foundation (DFG, project no. 314905040 and no. 493697503) and by German Cancer Aid (Deutsche Krebshilfe, project no. 70113922). S.V. is supported by Ministerio de Ciencia, Innovación y Universidades, Convocatoria 2019 para incentivar la Incorporación Estable de Doctores (IED2019-001007-I), by FEDER/Ministerio de Ciencia, Innovación y Universidades – Agencia Estatal de Investigación (PID2020‐116344‐RB‐100) and by the Government of Navarra-Health Research Department (58; 2018). J.V. is funded by Ministerio de Ciencia e Innovación, part of Agencia Estatal de Investigación (AEI), through the Retos Investigación grant number PID2019-108651RJ-I00/DOI 10.13039/501100011033. The authors thank CERCA Programme/Generalitat de Catalunya for institutional support. R.I.R.M. and J.J.G.M. are supported by Instituto de Salud Carlos III, Spain (PI20/00189, PI19/00819) co-funded by the European Union. L. Fouassier belongs to a team supported by the Fondation pour la Recherche Médicale (Equipe FRM 2020 no. EQU202003010517) and is supported by Inserm and Sorbonne Université, INCa and ITMO Cancer of Aviesan within the framework of the 2021–2030 Cancer Control Strategy, on funds administered by Inserm. |
| Source: |
ISSN: 1759-5045. |
| Publisher Information: |
HAL CCSD; Nature Publishing Group, 2009- |
| Publication Year: |
2023 |
| Collection: |
Université de Rennes 1: Publications scientifiques (HAL) |
| Subject Terms: |
[SDV]Life Sciences [q-bio]; [SDV.CAN]Life Sciences [q-bio]/Cancer; [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology |
| Description: |
International audience ; Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary tree. CCA has a poor prognosis, its clinical management remains challenging, and effective treatments are lacking. Therefore, preclinical research is of pivotal importance and necessary to acquire a deeper understanding of CCA and improve therapeutic outcomes. Preclinical research involves developing and managing complementary experimental models, from in vitro assays using primary cells or cell lines cultured in 2D or 3D to in vivo models with engrafted material, chemically induced CCA or genetically engineered models. All are valuable tools with well-defined advantages and limitations. The choice of a preclinical model is guided by the question(s) to be addressed; ideally, results should be recapitulated in independent approaches. In this Consensus Statement, a task force of 45 experts in CCA molecular and cellular biology and clinicians, including pathologists, from ten countries provides recommendations on the minimal criteria for preclinical models to provide a uniform approach. These recommendations are based on two rounds of questionnaires completed by 35 (first round) and 45 (second round) experts to reach a consensus with 13 statements. An agreement was defined when at least 90% of the participants voting anonymously agreed with a statement. The ultimate goal was to transfer basic laboratory research to the clinics through increased disease understanding and to develop clinical biomarkers and innovative therapies for patients with CCA. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/36755084; PUBMED: 36755084 |
| DOI: |
10.1038/s41575-022-00739-y |
| Availability: |
https://hal.science/hal-03979823; https://hal.science/hal-03979823v1/document; https://hal.science/hal-03979823v1/file/Calvisi%20et%20al%20-%202023%20-%20Criteria%20for%20preclinical%20models%20of%20cholangiocarcinoma%20_59081_2_art_file_529801_rhdbs3.pdf; https://doi.org/10.1038/s41575-022-00739-y |
| Rights: |
http://creativecommons.org/licenses/by-nc/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.1BFDC2A8 |
| Database: |
BASE |